Quality of life · adults and children with cystic fibrosis
1 finding from 1 review
Change in sputum P aeruginosa density at end of treatment (cfu/g) · adults and children with cystic fibrosis
Summary of findings: single showed no clear difference in change in sputum P aeruginosa density at end of treatment (cfu/g) compared with combination intravenous anti‐pseudomonal antibiotic therapy (moderate certainty).
2 findings from 1 review
Need for extra treatment · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Quality of life  · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (Functional Assessment of Cancer Therapy‐prostate [FACT‐P; range 0 to 156; higher values = better quality of life]) measured at 12 months · men with metastatic, hormone‐sensitive prostate cancer
1 finding from 1 review
Overall survival · people with advanced gastric cancer
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes overall survival compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
Taxane‐platinum‐fluoropyrimidine combinations may leads to higher tumour response compared with taxane‐platinum (without fluoropyrimidine) (low certainty).
1 finding from 1 review
Progression‐free survival · people with advanced gastric cancer
Taxane‐platinum‐fluoropyrimidine combinations probably leads to lower progression‐free survival compared with taxane‐platinum (without fluoropyrimidine) (moderate certainty).
1 finding from 1 review
Treatment‐related death · people with advanced gastric cancer
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment‐related death compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment discontinuation due to toxicity compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
1 finding from 1 review
Smoking cessation ‐ 16 weeks versus 8 weeks · people who smoke
It is very uncertain whether longer changes smoking cessation ‐ 16 weeks versus 8 weeks compared with shorter duration of combination nicotine replacement therapy (very low certainty).
1 finding from 1 review
Smoking cessation · people who smoke
Longer showed no clear difference in smoking cessation ‐ 6 weeks versus 2 weeks compared with shorter duration of combination nicotine replacement therapy (low certainty).
1 finding from 1 review
SAEs · people who smoke
It is very uncertain whether longer changes overall SAEs ‐ 26 weeks versus 8 weeks compared with shorter duration of combination nicotine replacement therapy (very low certainty).
3 findings from 1 review
RR 1.63 [0.6, 4.42]
1 study · 544 participants
Very low
no estimate extracted
1 study · 637 participants
Very low
no estimate extracted
1 study · 987 participants
Very low
Treatment withdrawal · people who smoke
1 finding from 1 review
Overall survival (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
1‐Year survival rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in 1‐year survival rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Response rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in response rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Adverse events: neurotoxicity (grade 3/4) ( · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin probably leads to higher grade III or IV neurotoxicity compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin probably leads to higher grade III or IV thrombocytopenia compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review